C H Chang1, K Y Chen, M Y Lai, K A Chan. 1. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
AIM: To use meta-analysis to study the risk of anaemiarelated to ribavirin therapy for chronic hepatitisC. METHODS: The MEDLINE database up to January 2001 was searched for randomized controlled trials of ribavirin (monotherapy or combined with interferon) for chronic hepatitis C. The outcomes evaluated were withdrawal from the study due to anaemia, ribavirin dosage reduction due to a decrease in haemoglobin and haemoglobin levels below 10 g/dL. RESULTS: Based on 17 studies, the overall risk difference (ribavirin vs. no ribavirin) for anaemia was 0.09 [95% confidence interval (CI), 0.04-0.13]. Two Asian studies reported risk differences of 0.29 and 0.22, greater than the pooled risk difference of 0.07 (95% CI, 0.03-0.12) for 15 non-Asian studies. The risk associated with 1 g or more of ribavirin per day was higher (risk difference, 0.09; 95% CI, 0.04-0.14) than that for 0.8 g of ribavirin per day (risk difference, 0.01; 95% CI, - 0.04-0.06). CONCLUSIONS: Chronic hepatitis C patients treated with 1 g or more of ribavirin per day were at a higher risk of developing anaemia. Reported risks were higher among Asian studies, which may be due to differences in study entrance criteria, dosage titration strategy or ethnic vulnerability.
AIM: To use meta-analysis to study the risk of anaemiarelated to ribavirin therapy for chronic hepatitisC. METHODS: The MEDLINE database up to January 2001 was searched for randomized controlled trials of ribavirin (monotherapy or combined with interferon) for chronic hepatitis C. The outcomes evaluated were withdrawal from the study due to anaemia, ribavirin dosage reduction due to a decrease in haemoglobin and haemoglobin levels below 10 g/dL. RESULTS: Based on 17 studies, the overall risk difference (ribavirin vs. no ribavirin) for anaemia was 0.09 [95% confidence interval (CI), 0.04-0.13]. Two Asian studies reported risk differences of 0.29 and 0.22, greater than the pooled risk difference of 0.07 (95% CI, 0.03-0.12) for 15 non-Asian studies. The risk associated with 1 g or more of ribavirin per day was higher (risk difference, 0.09; 95% CI, 0.04-0.14) than that for 0.8 g of ribavirin per day (risk difference, 0.01; 95% CI, - 0.04-0.06). CONCLUSIONS:Chronic hepatitis Cpatients treated with 1 g or more of ribavirin per day were at a higher risk of developing anaemia. Reported risks were higher among Asian studies, which may be due to differences in study entrance criteria, dosage titration strategy or ethnic vulnerability.
Authors: Rinaldo Pellicano; Antonio Craxi; Piero-Luigi Almasio; Mario Valenza; Giovanna Venezia; Alfredo Alberti; Silvia Boccato; Luigi Demelia; Orazio Sorbello; Antonino Picciotto; Francesco Torre; Gaetano Ideo; Carlo Cattaneo; Mara Berrutti; Mario Rizzetto Journal: World J Gastroenterol Date: 2005-08-07 Impact factor: 5.742
Authors: Kanwal Baloch; Liqiong Chen; Ameer A Memon; Laura Dexter; William Irving; Mohammad Ilyas; Brian J Thomson Journal: Antivir Chem Chemother Date: 2017-01-01
Authors: Kelly M Grotzinger; Zobair M Younossi; Edoardo G Giannini; Pei-Jer Chen; Regina Rendas-Baum; Dickens Theodore Journal: Health Qual Life Outcomes Date: 2016-03-22 Impact factor: 3.186